Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG

  title={Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG},
  author={Michele Tameris and Helen McShane and J. Bruce McClain and Bernard S. Landry and Stephen Lockhart and Angelique K.K. Luabeya and Hennie D. Geldenhuys and Jacqui Shea and Gregory Dudley Hussey and Linda van der Merwe and Marwou de Kock and Thomas J Scriba and Robert E. Walker and Willem Albert Hanekom and Mark Hatherill and Hassan Mahomed},
BACKGROUND New tuberculosis (TB) vaccines are being developed to combat the global epidemic. A phase IIb trial of a candidate vaccine, MVA85A, was conducted in a high burden setting in South Africa to evaluate proof-of-concept efficacy for prevention of TB in infants. OBJECTIVE To describe the study design and implementation lessons from an infant TB vaccine efficacy trial. METHODS This was a randomised, controlled, double-blind clinical trial comparing the safety and efficacy of MVA85A to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
11 Citations
40 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 11 extracted citations


Publications referenced by this paper.
Showing 1-10 of 40 references


  • SM Graham, T Ahmed, F Amanullah, R Browning, V Cardenas, children et al. Evaluation of tuberculosis diagnostics in
  • Proposed clinical case definitions for M…
  • 2013

, MVA 85 A , induces durable antigen - speci fi c responses 14 months after vaccination in African infants

  • MO Ota, AA Odutola, PK Owiafe, S Donkor, OA Owolabi
  • 2012

Similar Papers

Loading similar papers…